Loading...
NPI 1346472859 · Oakhurst, NJ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Genesis Laboratory Management, LLC is a clinical medical laboratory provider located in Oakhurst, New Jersey. This profile covers 85 Medicare and 64 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Genesis Laboratory Management, LLC |
| Address | 1912 Route 35 Ste 202 |
| City | Oakhurst |
| State | NJ |
| ZIP | 07755 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 17, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $21.8M |
| Medicare | $5.5M |
GENESIS LABORATORY MANAGEMENT, LLC has a clinical laboratory profile dominated by molecular infectious-disease testing and pathology ancillary services: its top Medicare codes include high-volume molecular panels such as 87506 and respiratory/viral panels like U0004/U0002/U0005, alongside pathology stain and in situ hybridization codes (88364, 88365, 88342). The presence of both high-volume nucleic acid amplification codes and numerous pathology staining/CPT surgical pathology codes suggests a mixed operation that performs large-scale infectious-disease diagnostics as well as histopathology support for clinical care.
Medicaid billing is heavily concentrated in COVID-19 high-throughput PCR testing: code U0004 alone accounts for $14M and 64.7% of this provider’s total Medicaid revenue, and the top three Medicaid codes together account for 82.4% of Medicaid revenue. This extreme concentration indicates that Medicaid revenue is largely driven by pandemic-era SARS-CoV-2 diagnostic volume rather than a broad spread of routine lab services.
Medicare revenue shows notable concentration as well: the top three Medicare codes by revenue represent 45.9% of the provider’s Medicare revenue. Key Medicare drivers include 87506 (26.6% of Medicare revenue) and large-ranking pathology codes such as 88364 (6.3%) and 88305 (6.3%), indicating that Medicare dollars are split between multiplex infectious-agent panels and pathology services.
The provider’s payer mix is skewed toward Medicaid in scale: lifetime Medicaid revenue is $21.8M versus total Medicare revenue of $5.5M, making Medicaid the dominant payer relationship on which much of overall revenue depends. This means that changes in state Medicaid testing policies or demand for SARS-CoV-2 testing could materially impact the provider’s revenue profile.
GENESIS ranks as a regional/state leader for several Medicaid codes and as an outlier nationally on multiple Medicare codes. In-state, it ranks #1 of 67 providers for U0004 (100th percentile) and is top-ranked for several other Medicaid high-volume testing codes; nationally for Medicare, it ranks #1 of 604 providers for 88364 and #2 of 90 for 87506 (99–100th percentiles), signaling unusually high volumes relative to peers for those specific services.
Several specific CPT/HCPCS codes are statistical outliers or extreme outliers versus peers, highlighting areas of specialized scale: on Medicare, 87506 is described as an "extreme outlier, far above typical national volume," and 88364 and 0241U also appear as extreme outliers or top-percentile performers. On Medicaid, U0004 is an "extreme outlier, far above typical state volume." These designations point to dominant throughput for particular tests rather than evenly distributed lab activity.
The mix of very high claim counts for some surveillance/respiratory codes (e.g., Medicaid U0004 at 225.1K claims and U0005 at 159.1K claims) alongside sizable counts for pathology staining and in situ hybridization suggests the lab operates both as a high-throughput diagnostic testing hub and as a referral pathology service. Operationally, that combination implies capacity for large batch molecular workflows and specialized histopathology interpretation.
Provider tenure is long enough to establish operational stability: the NPI was enumerated on 2009-08-17 (~17 years ago). This multi-year presence combined with concentrated high-volume code activity suggests an established lab that has scaled particular services (notably SARS-CoV-2 testing and specific pathology assays) over time.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
85 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87506 | The lab analyst performs a test to detect six to eleven types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that cause gastrointestinal… | 5,150 | $260 | $1.3M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 19,010 | $30 | $646.4K |
| 88364 | The lab analyst applies an additional in situ hybridization single probe stain on a slide or slides prepared from the same patient specimen as the initial probe stain, such as tumor tissue. Then a… | 3,440 | $90 | $316.8K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 9,520 | $30 | $314.2K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 4,480 | $60 | $282.2K |
| 83520 | The lab analyst measures the analyte, which is not an infectious agent antibody or infectious agent antigen, by immunoassay. Use 83520 for procedures that have no specific code assigned for the… | 14,390 | $20 | $244.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 5,430 | $30 | $184.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2,250 | $70 | $166.6K |
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 320 | $480 | $154.9K |
| 0241U | N/A | 1,050 | $140 | $147.1K |
Showing 1–10 of 85
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 85 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
85 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87506 | 2 | 10 | 110 | $260 | $506.1K |
| 87798 | 13 | 40 | 1,760 | $30 | $284.3K |
| 88120 | 7 | 20 | 200 | $350 | $278K |
| 87150 | 2 | 10 | 430 | $30 | $175.3K |
| U0004 | 5 | 20 | 360 | $70 | $116.2K |
| 83880 | 30 | 50 | 70 | $40 | $83.4K |
| 82306 | 89 | 250 | 50 | $30 | $79K |
| 88305 | 11 | 290 | 720 | $40 | $71.8K |
| 87801 | 9 | 20 | 300 | $70 | $70.5K |
| 84443 | 86 | 380 | 100 | $20 | $65.5K |
Showing 1–10 of 85
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
64 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 225,110 | $60 | $14M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 159,090 | $20 | $2.9M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 2,960 | $320 | $960K |
| 0241U | N/A | 7,160 | $90 | $659.1K |
| 88364 | The lab analyst applies an additional in situ hybridization single probe stain on a slide or slides prepared from the same patient specimen as the initial probe stain, such as tumor tissue. Then a… | 3,270 | $180 | $594.2K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 1,470 | $290 | $422.5K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 8,490 | $40 | $356.7K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 7,220 | $40 | $295.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 8,530 | $30 | $255.8K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 6,760 | $30 | $202.8K |
Showing 1–10 of 64
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
64 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 122 | 130 | 3,180 | $60 | $4.2M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 70 | 4,800 | $50 | $1M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 109 | 120 | 900 | $20 | $971.9K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 106 | 120 | 940 | $20 | $957.4K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 43 | 50 | 400 | $10 | $839.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 10 | 140 | 5,590 | $20 | $823.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 9 | 90 | 630 | $30 | $806.2K |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 23 | 60 | 280 | $40 | $728.3K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 6 | 30 | 630 | $20 | $687.4K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 38 | 50 | 300 | $20 | $629.9K |
Showing 1–10 of 64
Other providers in the same ZIP code as Genesis Laboratory Management, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ocean Surgical Pavilion, PC | NJ | Ambulatory Surgical Clinic/Center | $927K | $0 |
| Sukrut Dwivedi | NJ | Infectious Disease Physician | $572.1K | $0 |
| Thomas Rich | NJ | Podiatrist | $533.4K | $1.2K |
| Aaron Morgan | NJ | Dermatology Physician | $505.2K | $0 |
| Aleksey Kretov | NJ | Internal Medicine Physician | $446.2K | $0 |
| Thomas Lake | NJ | Colon & Rectal Surgery Physician | $196.7K | $0 |
| Reza Akhtar | NJ | Gastroenterology Physician | $182.7K | $0 |
| Ferris Ginsberg | NJ | Diagnostic Radiology Physician | $180.9K | $0 |
| Emmanuel Barias | NJ | Family Medicine Physician | $156.7K | $0 |
| Jeffrey Mobilio | NJ | Physician Assistant | $144.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.